NCT04546789View on ClinicalTrials.gov

Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

May 16, 2021

Study Completion Date

May 16, 2021

Conditions
Hepatic Impairment
Interventions
DRUG

M2951 (BTK inhibitor)

Participants will receive a single oral dose of M2951 (BTK inhibitor).

Trial Locations (1)

Unknown

CRS Clinical Research Services Kiel GmbH, Kiel

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04546789 - Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK | Biotech Hunter | Biotech Hunter